GeneOne Life Science (011000)

KOSPI · 2,670 KRW · As of Aug 26, 2026 close

1Y Close · As of Aug 26, 2026

Mkt Cap

48.5B

Rev (2025)

23.0B

Op Inc (2025)

-44.0B

Net Inc (2025)

-51.9B

PBR

1.19

52W

0K~2K

GeneOne Life Science operates in the Pharmaceuticals sector.

Legal name: GeneOne Life Science, Inc.

In fiscal year 2025, GeneOne Life Science (011000) reported revenue of 23.0 billion KRW, down 35.5% from 35.7 billion KRW a year earlier.

Operating profit was -44.0 billion KRW and net income was -51.9 billion KRW in the same year.

As of the Aug 26, 2026 close, the market capitalization was 48.5 billion KRW, with a P/B of 1.19.

These figures can be verified in the DART filing (receipt no. 20260407003512).

Year	Rev	Op Inc	Net Inc
2025	23.0B	-44.0B	-51.9B
2024	35.7B	-43.0B	-48.5B
2023	40.2B	-48.4B	-77.8B

5 applicable out of 8 items

Semi-Annual Adverse Opinion or Full Capital Erosion

Semi-Annual Report (2026.06)

기타시장안내 (기업심사위원회 심의대상 결정)

Checks

5 of 8 checked items currently applicable.

Market Cap & Price: Market cap is above the delisting threshold.

Administrative Designation: 1 administrative designation criteria met. [source]

Audit Opinion: Audit opinion: Unqualified (clean).

Convertible Bonds: Convertible bonds outstanding with 0.3% potential dilution.

Capital Increase: 3 capital-increase filing(s) in the last 180 days. [source]

Treasury Stock: No treasury stock filings.

Embezzlement & Litigation: 1 embezzlement/litigation filing(s) in the last 180 days. [source]

Major Shareholder Change: No major shareholder changes in the last 180 days.

Market Action: 2 market action(s) (trading halt, delisting, etc.) recorded. [source]

These checks are mechanical tests of disclosed figures and do not constitute investment advice or recommendations.

Date	Filing
2026-08-14	Semi-Annual Adverse Opinion or Full Capital Erosion
2026-08-14	Semi-Annual Report (2026.06)
2026-08-07	기타시장안내 (기업심사위원회 심의대상 결정)
2026-08-06	Other Business Matters (Voluntary Disclosure)
2026-08-06	대표이사(대표집행임원)변경(안내공시)